This protocol applies to patients with metastatic renal cell carcinoma of the papillary subtype (pRCC) — a histologically distinct subtype that warrants a specific first-line systemic treatment approach.
For metastatic papillary RCC, a specific systemic agent is recommended based on a positive randomised controlled trial. Combination-based regimens are also among the options considered for this subtype.
Full regimen details, sequencing, and the complete range of options are available in the structured protocol below.